Process analytical technology for CGTs – the big discussion

4 September 2023
Advanced Therapy Medicinal Products
Sarah Currie
Phorum Director

Process analytical technology (PAT) integrates analytical technologies into the biomanufacturing process to achieve the timely measurement of process parameters and product quality attributes. For new and emerging complex biologics – such as cell, gene, and RNA therapies (CGTs) designed for patients with high medical needs and typically manufactured in small batch sizes with short shelf lives – there is a need for speed and deeper process understanding. CGTs stand to benefit greatly from employing PAT.

However, with unique critical quality attributes, complex mechanism of actions and heterogenicity issues, developing PAT approaches for CGTs will likely present additional new challenges than those encountered with PAT for more established biologics (e.g., monoclonal antibodies). These may be best addressed by industry working collaboratively.

This is why BioPhorum Cell and Gene Therapy brought together 198 subject matter experts from 40 different CGT companies for a two-day virtual event in March 2023. This focused on understanding the challenges and opportunities for PAT in the CGT space, performing industry benchmarking activities, and sharing case studies and suggestions that may ultimately accelerate the implementation of PAT. 

The output from the event is summarized in A commentary on the current process analytical technology status and opportunities for cell and gene therapies.  

Our commentary summarizes the CGT industry views on PAT articulated during the virtual event and documents key takeaways on the benefits and barriers to PAT. It also notes the unique considerations for PAT in the context of CGTs and highlights some near-term options to help you accelerate these important therapies to patients before implementing PAT.

To look at the application of PAT tools for CGT modalities, we conducted a pre-event benchmarking survey that gathered feedback from 28 experts from 21 different CGT companies. The findings include:

  • Only 25% of respondents have started to implement PAT, while 50% intend to implement PAT in the near future (of which, the majority currently focus on in vivo gene therapy and in the non-GMP environment)
  • Only two had initiated any regulatory discussions related to PAT implementation
  • Where PAT is being used, it is mostly seen in upstream processing steps – there is more work to do to achieve its widespread adoption in both upstream and downstream processing.

The event also featured a PAT lab of the future virtual tour and the opportunity for attendees to discuss quality system improvements that could provide options to reduce batch release turnaround times irrespective of the PAT status.

The consensus from the event is that, for these complex modalities where process understanding is inherently poorer than for more established biologics, PAT adoption has the potential to transform CGT process characterization and manufacturing, expediting these life-changing therapies to patients. Our paper is a great contribution to the debate and lays the groundwork for future collaborative work with industry, regulators, and suppliers working together to advance PAT integration to realize improvements in process control that are fit for CGTs.

For more information, download the paper here and contact Sarah Currie, Senior Account Manager, at

Digital 3D Computer
How to maximize business value from process analytical technologies

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Inaugural BioPhorum Quality face to face – get involved
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
Delivering a Cell and Gene Therapy Outbound Supply Chain Pathway for the Industry
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
A major milestone – a harmonized approach to product carbon footprint data
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing